INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 459m ago
HOUSE PTR59m ago
SEC 13F59m ago
ROBINHOOD CHAIN59m ago
Corporate insider
FJ

Friedl-Naderer Johanna

Chief Commercial OfficerCIK 0001915598

EDGAR filingsOpen in network
Disclosed transactions3
Buys / sells0 / 3
Max Insider Score10
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
6
FJ
Friedl-Naderer JohannaChief Commercial Officer
DYNDyne Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$22K
900 sh
Sep 4, 2026Sep 8, 2026
traded Sep 4, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Dyne Therapeutics, Inc.Chief Commercial Officer · Aug 17, 2026
6
FJ
Friedl-Naderer JohannaChief Commercial Officer
DYNDyne Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL
$3,493
185 sh
Sep 8, 2026
Sep 8, 2026
traded Sep 8, 2026
+0d
SEC FORM 4

Evidence

10
FJ
Friedl-Naderer JohannaChief Commercial Officer
DYNDyne Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$5,939
226 sh
Aug 13, 2026Aug 17, 2026
traded Aug 13, 2026
+4dSEC FORM 4

Evidence